Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
- Mechanism
- Curator reviewed
Caprospinol cleared beta-amyloid plaque formation and restored memory capacity in-vivo; confirming in-vitro studies showing Caprospinol binds ß-amyloid directly and inhibits the formation of neurotoxic amyloid-derived diffusible ligands (ADDLs) by forming stable heavy complexes with the peptide. In addition, the studies demonstrated Caprospinol protects mitochondria function, thus protecting cell viability and decreased cell death.
- Primary indication
- Alzheimer's DiseaseCurator reviewed
- Formula / weight
- C33H52O4 · 512.775 g/mol (avg)
- Also known as
- Diosgenin caproate
- Code names
- J2.343.184J · SP-233
Resolves to
VMOZFSWFUBLCNN-AAPULDEBSA-NSMILES[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@H](CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2)OC(=O)CCCCCWhat you can answer from here — as of July 03, 2026
Which drugs share a target with Caprospinol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account